FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Sagrario Martin-Aragon

Research Profile

Chemicals & Drugs

Physiology

Procedures

Disorders

Co-author Network

Publications

TOP 3
Karim Jiménez-Aligaga; Sagrario Martin-Aragon; Paloma Bermejo-Bescós; Aurelio G Csákÿ
Discovery of alkenylboronic acids as neuroprotective agents affecting multiple biological targets involved in Alzheimer's disease.
María Muñoz; Carmen Romero; Juana Benedi; Paloma Bermejo-Bescós; Sagrario Martin-Aragon
SNP-mediated neuroprotection under glucose deprivation is enhanced by Hypericum perforatum.
Vassilios I Avramis; Sagrario Martin-Aragon; Earl V Avramis; Barbara L Asselin
Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Sagrario Martin-Aragon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Karim Jiménez-Aligaga; Sagrario Martin-Aragon; Paloma Bermejo-Bescós; Aurelio G Csákÿ
Discovery of alkenylboronic acids as neuroprotective agents affecting multiple biological targets involved in Alzheimer's disease.
Bioorganic & medicinal chemistry letters 2013;23(2):426-9.
2012: María Muñoz; Carmen Romero; Juana Benedi; Paloma Bermejo-Bescós; Sagrario Martin-Aragon
SNP-mediated neuroprotection under glucose deprivation is enhanced by Hypericum perforatum.
CNS & neurological disorders drug targets 2012;11(2):162-73.
2007: Vassilios I Avramis; Sagrario Martin-Aragon; Earl V Avramis; Barbara L Asselin
Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Anticancer research 2007;27(4C):2561-72.
2004: Eduard H Panosyan; Nita L Seibel; Sagrario Martin-Aragon; Paul S Gaynon; Ioannis A Avramis; Harland Sather; Janet Franklin; James B Nachman; Lawrence J Ettinger; Mei K La; Peter G Steinherz; Lewis J Cohen; Stuart E Siegel; Vassilios I Avramis
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.
Journal of pediatric hematology/oncology 2004;26(4):217-26.
2001: C H Fu; Sagrario Martin-Aragon; KI Weinberg; V C Ardi; P V Danenberg; Vassilios I Avramis
Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein.
Cancer chemotherapy and pharmacology 2001;48(2):123-33.
2001: Fataneh Majlessipour; R Kwock; Sagrario Martin-Aragon; KI Weinberg; Vassilios I Avramis
Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.
Anticancer research 2001;21(1A):11-22.
2000: Sagrario Martin-Aragon; S K Mukherjee; B J Taylor; S P Ivy; C H Fu; V C Ardi; Vassilios I Avramis
Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Anticancer research 2000;20(1A):139-50.